Medical treatment of cushing's disease

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 425-438

  Feelders, Richard A ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CORTICOTROPIN; CYPROHEPTADINE; DOPAMINE RECEPTOR; ENZYME INHIBITOR; ETOMIDATE; FLUCONAZOLE; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; KETOCONAZOLE; LCI 699; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; OXYGENASE; PASIREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RETINOIC ACID; SOMATOSTATIN RECEPTOR; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE; UNCLASSIFIED DRUG; VALPROIC ACID;

ACNE; ACUTE PSYCHOSIS; ADVERSE OUTCOME; CLINICAL EFFECTIVENESS; CUSHING DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TREATMENT FAILURE; ENDOMETRIUM HYPERPLASIA; ENZYME ACTIVITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HUMAN; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERTENSION; HYPOGONADISM; HYPOKALEMIA; INFECTION; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROLACTINOMA; QUALITY OF LIFE; REVIEW; STEROIDOGENESIS; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; DOPAMINE AGONISTS; HUMANS; MITOTANE; OCTREOTIDE; PITUITARY ACTH HYPERSECRETION; RECEPTORS, GLUCOCORTICOID; SOMATOSTATIN;

EID: 84873622229     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3126     Document Type: Review

References (105)

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367:1605-1617.
2. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007;92:976-981.
3. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454-2462.
4. Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab. 1996;81:2647-2652.
5. Atkinson AB, Kennedy A, Wiggam MI, et al. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005;63:549-559.
6. Patil CG, Prevedello DM, Lad SP, et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab. 2008;93:358-362.
7. Patil CG, Veeravagu A, Prevedello DM, Katznelson L, Vance ML, Laws ER Jr. Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease. Neurosurgery. 2008;63:266-270; discussion 270-271.
8. Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. 1997;336:172-177.
9. Castinetti F, Nagai M, Dufour H, et al. Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. Eur J Endocrinol. 2007;156:91-98.
10. Becker G, Kocher M, Kortmann RD, et al. Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol. 2002;178:173-186.
11. van Aken MO, Pereira AM, Biermasz NR, et al. Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab. 2005;90:3279-3286.
12. Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML, Young WF Jr. Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience. Clin Endocrinol (Oxf). 2008;68:513-519.
13. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing's disease (CD): clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167:311-326.
14. Pereira AM, Tiemensma J, Romijn JA. Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology. 2010;92(suppl 1): 65-70.
15. Loosen PT, Chambliss B, DeBold CR, Shelton R, Orth DN. Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry. 1992;25:192-198.
16. Sonino N, Fava GA, Raffi AR, Boscaro M, Fallo F. Clinical correlates of major depression in Cushing's disease. Psychopathology. 1998;31:302-306.
17. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994; 40:479-484.
18. Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA. Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. Eur J Endocrinol. 2010;162:331-340.
19. Stuijver DJ, van Zaane B, Feelders RA, et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab. 2011;96:3525-3532.
20. van der Pas R, de Bruin C, Leebeek FW, et al. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab. 2012;97:1303-1310.
21. Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86:117-123.
22. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96:632-642.
23. Hammer GD, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab. 2004;89:6348-6357.
24. Swearingen B, Biller BM, Barker FG II, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. AnnInternMed. 1999;130:821-824.
25. Bolland MJ, Holdaway IM, Berkeley JE, et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol (Oxf). 2011;75:436-442.
26. Hassan-Smith ZK, Sherlock M, Reulen RC, et al. Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab. 2012;97:1194-1201.
27. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88:2527-2533.
28. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf). 2004;61:768-777.
29. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84:2664-2672.
30. Manetti L, Bogazzi F, Giovannetti C, et al. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery. Eur J Endocrinol. 2010;163:783-791.
31. DiSomma C, Pivonello R, Loche S, et al. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf). 2003;58:302-308.
32. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab. 1997;82:912-919.
33. Morris D, Grossman A. The medical management of Cushing's syndrome. Ann NY Acad Sci. 2002;970:119-133.
34. Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology. 2010;92(suppl 1):111-115.
35. Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab. 2000;85:42-47.
36. Russi E, Speich R, Hess T, Meili E, Walter E. Pneumocystis carinii pneumonia after transsphenoidal removal of microadenoma causing Cushing's syndrome. Lancet. 1993;341:1348-1349.
37. Mezey E, Hunyady B, Mitra S, et al. Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary. Endocrinology. 1998;139:414-419.
38. de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94:1118-1124.
39. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J. 2009;56:579-584.
40. Batista DL, Zhang X, Gejman R, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006;91: 4482-4488.
41. Saveanu A, Jaquet P. Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord. 2009;10: 83-90.
42. Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152:645-654.
43. Duran-Prado M, Gahete MD, Martinez-Fuentes AJ, et al. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab. 2009;94:2634-2643.
44. de Bruin C, Feelders RA, Waaijers AM, et al. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol. 2009; 42:47-56.
45. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78: 189-225.
46. Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, Hofland LJ. Novel insights in dopamine receptor physiology. Eur J Endocrinol 2007;156(suppl. 1):S13-S21.
47. Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89:2452-2462.
48. Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine. 2001;14:329-336.
49. Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev. 1996;17:245-261.
50. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 2006;126:789-799.
51. Lamberts SW. Glucocorticoid receptors and Cushing's disease. Mol Cell Endocrinol. 2002;197:69-72.
52. Huizenga NA, de Lange P, Koper JW, et al. Human adrenocorticotropin- secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. J Clin Endocrinol Metab. 1998;83:917-921.
53. Korbonits M, Bujalska I, Shimojo M, et al. Expression of 11 β-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. J Clin Endocrinol Metab. 2001;86:2728-2733.
54. Tateno T, Izumiyama H, Doi M, et al. Differential gene expression in ACTH-secreting and non-functioning pituitary tumors. Eur J Endocrinol. 2007;157:717-724.
55. Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev. 2006;20:2871-2886.
56. Drouin J, Bilodeau S, Vallette S. Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency. Clin Genet. 2007;72:175-182.
57. Stalla GK, Brockmeier SJ, Renner U, et al. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol. 1994;130:125-131.
58. Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201-995 onACTHsecretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh). 1989;120:760-766.
59. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitarydependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94:115-122.
60. Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med. 2010;362:1846-1848.
61. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012; 366:914-924.
62. Bertherat J, Schopohl J, Ludlam WH, et al. Long-term pasireotide use leads to significant and sustained improvements in the signs and symptoms of Cushing disease: 24-month results from a randomized phase III study. Endocr Rev. 2012;33(suppl):SUN-734.
63. Henry R, Mudaliar S, Wetli-Hermosillo K, Ligueros-Saylan M, Chenji S, Golor G. Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocr Rev. 2011;32(suppl):P3-274.
64. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology. 2002;143:4123-4130.
65. Lamberts SW, Klijn JG, de Quijada M, et al. The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. J Clin Endocrinol Metab. 1980;51:307-311.
66. Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev. 1993;14:443-458.
67. Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary. 2010;13:123-129.
68. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94:223-230.
69. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;163:709-716.
70. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29-38.
71. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356:39-46.
72. Delgado V, Biermasz NR, van Thiel SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf). 2012;77:99-105.
73. Labeur M, Paez-Pereda M, Arzt E, Stalla GK. Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas. Rev Endocr Metab Disord. 2009;10:103-109.
74. Castillo V, Giacomini D, Paez-Pereda M, et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology. 2006;147:4438-4444.
75. Pecori Giraldi F, Ambrogio AG, Andrioli M, et al. Potential role for retinoic acid in patients with Cushing's disease. J Clin Endocrinol Metab. 2012;97:3577-3583.
76. Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002;8:1281-1287.
77. Heaney AP, Fernando M, Melmed S. PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest. 2003;111: 1381-1388.
78. Ambrosi B, Dall'Asta C, Cannavo S, et al. Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease. Eur J Endocrinol. 2004;151:173-178.
79. Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab. 2005;90:1340-1346.
80. Pecori Giraldi F, Scaroni C, Arvat E, et al. Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf). 2006;64:219-224.
81. Schteingart DE. Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs. 2009;14:661-671.
82. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005;6:386-394.
83. Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2011;75:585-591.
84. Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. NEngl J Med. 1979; 300:459-464.
85. Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol. 2012;167:473-481.
86. Nader N, Raverot G, Emptoz-Bonneton A, et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab. 2006; 91:2165-2170.
87. Alexandraki KI, Kaltsas GA, le Roux CW, et al. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin Endocrinol (Oxf). 2010; 72:305-311.
88. Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol. 2012;167:137-143.
89. Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1991;35:169-178.
90. Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CR, Besser GM. Metyrapone in long-term management of Cushing's disease. Br Med J. 1977;2:215-217.
91. Engelhardt D, Weber MM, Miksch T, Abedinpour F, Jaspers C. The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin Endocrinol (Oxf). 1991; 35:163-168.
92. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987;317:812-818.
93. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol. 2008;158:91-99.
94. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509-533.
95. Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo-and active-controlled phase 2 trial. Circulation. 2011;124:1945-1955.
96. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010; 56:831-838.
97. Pivonello R, Fleseriu M, Guignat L, et al. Patients with Cushing's disease achieve normal urinary cortisol with LCI699, a potent 11-β-hydroxylase inhibitor; preliminary results from a multicenter, proof-of-concept study. Endocr Rev. 2012;33(suppl 1):OR49-1.
98. van der Pas R, Hofland L, Hofland J, et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol. 2012; 215:403-412.
99. Castinetti F, Brue T, Conte-Devolx B. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes. 2012;19:295-299.
100. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-2049.
101. de Bruin C, Hofland LJ, Nieman LK, et al. Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab. 2012;97:455-462.
102. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of heterooligomers with enhanced functional activity. Science. 2000;288: 154-157.
103. Feelders RA, De Bruin C, Pereira AM, et al. Medical treatment of Cushing's disease with pasireotide mono- or combination therapy with cabergoline and ketoconazole modulates somatostatin receptor subtype expression on corticotroph tumor cells [abstract OR14-6]. Endocr Rev. 2010;31(suppl 1):S845.
104. Kamenicky P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 2011;96:2796-2804.
105. van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA. Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment [published online ahead of print November 7, 2012]. Clin Endocrinol (Oxf). doi:10.1111/cen.12094.